Yüklüyor......
Prospective Evaluation of the Impact of the 21‐Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node‐Positive Breast Cancer in Ontario, Canada
BACKGROUND. The 21‐gene Recurrence Score (RS) assay is only reimbursed in Ontario for node‐negative and micrometastatic node‐positive (N+) early‐stage breast cancer (EBC). We carried out a prospective study to evaluate the impact of the assay on treatment decisions for women with N+ EBC. SUBJECTS, M...
Kaydedildi:
| Yayımlandı: | Oncologist |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AlphaMed Press
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6058344/ https://ncbi.nlm.nih.gov/pubmed/29371476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0346 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|